pembrolizumab
Showing 1 - 25 of 1,067
Cancer Trial in Villejuif (Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant)
Not yet recruiting
- Cancer
- Pembrolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Oct 30, 2023
MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)
Not yet recruiting
- MSI-H Colorectal Cancer
- Regorafenib
- Pembrolizumab
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Aug 17, 2023
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)
Not yet recruiting
- Solid Tumor
- +2 more
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Sep 7, 2023
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Advanced Solid Tumors Trial (AMG 355, Pembrolizumab)
Not yet recruiting
- Advanced Solid Tumors
- AMG 355
- Pembrolizumab
- (no location specified)
Nov 9, 2023
Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Pembrolizumab
-
Cologne, Germany1st Department of Medicine, Cologne University Hospital
Sep 19, 2023
Lung Cancer Trial (Sacituzumab Govitecan, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- Sacituzumab Govitecan
- Pembrolizumab
- (no location specified)
Sep 20, 2023
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Pembrolizumab
- +7 more
-
Beijing, Beijing, ChinaBeijing Tongren Hospital
Oct 26, 2023
GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)
Recruiting
- GastroEsophageal Cancer
- Gastric Cancer
- Neratinib
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 25, 2023
Sinonasal Undifferentiated Carcinoma Trial in Pavia (Pembrolizumab)
Not yet recruiting
- Sinonasal Undifferentiated Carcinoma
- Pembrolizumab
-
Pavia, Lombardia, ItalyIstituti Clinici Scientifici Maugeri
Jun 21, 2023
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)
Not yet recruiting
- Pancreatic Cancer
- Gemcitabine
- +2 more
-
Baltimore, MarylandSKCCC Johns Hopkins
Aug 16, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
- Ramucirumab
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)
Not yet recruiting
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma
- GB1211
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Jun 19, 2023
Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)
Not yet recruiting
- Cholangiocarcinoma
- Pembrolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2023
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer Trial in Nashville (drug, biological,
Not yet recruiting
- Limited Stage Lung Small Cell Carcinoma
- +3 more
- Cisplatin
- +8 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Nov 10, 2023
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,
Not yet recruiting
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 18, 2023
Differentiated Thyroid Cancer Trial in Pavia (Pembrolizumab)
Not yet recruiting
- Differentiated Thyroid Cancer
- Pembrolizumab
-
Pavia, Lombardia, ItalyIstituti Clinici Scientifici Maugeri
May 5, 2023
Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)
Not yet recruiting
- Head and Neck Neoplasms
- TransCon TLR7/8 Agonist
- +2 more
- (no location specified)
Aug 4, 2023
Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors Trial run by the National
Not yet recruiting
- Adenocarcinoma of the Bladder
- +2 more
- Enfortumab vedotin
- Pembrolizumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Sep 22, 2023
Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Sacituzumab govitecan
- Pembrolizumab
- (no location specified)
Oct 5, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023